A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance

Drug Safety

Volumn 38, Issue 8, 2015, Pages 749-765

  Xu, Yihua ^a   Zhou, Xiaofeng ^b   Suehs, Brandon T ^a   Hartzema, Abraham G ^c   Kahn, Michael G ^d   Moride, Yola ^e   Sauer, Brian C ^f   Liu, Qing ^b   Moll, Keran ^a   Pasquale, Margaret K ^a   Nair, Vinit P ^a   Bate, Andrew ^b  

^a HUMANA INC   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d Children's Hospital Colorado   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BENZODIAZEPINE; CARBAMAZEPINE; INDOMETACIN; KETOROLAC; VALPROIC ACID;

ACUTE HEART INFARCTION; ALGORITHM; ANALYTIC METHOD; ANAPHYLAXIS; ARTICLE; COMPARATIVE STUDY; DATA ANALYSIS; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL HEMORRHAGE; HIP FRACTURE; HUMAN; LIVER INJURY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; COHORT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; POSTMARKETING SURVEILLANCE; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA;

COHORT STUDIES; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORDS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; SENTINEL SURVEILLANCE;

EID: 84938203893     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0297-5     Document Type: Article

References (27)

1. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel system—a national resource for evidence development. N Engl J Med. 2011;364(6):498–9. doi:10.1056/NEJMp1014427.
2. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects–advantages and disadvantages. Nat Clin Pract Rheumatol. 2007;3(12):725–32. doi:10.1038/ncprheum0652.
3. Brown JS, Holmes JH, Shah K, Hall K, Lazarus R, Platt R. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010;48(6 Suppl):S45–51. doi:10.1097/MLR.0b013e3181d9919f.
4. Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600–6.
5. Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(S1):23–31.
6. McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiol Drug Saf. 2012;21:18–22. doi:10.1002/pds.2319.
7. Observational Medical Outcomes Partnership. OMOP project website. http://omop.fnih.org. Accessed 15 May 2015.
8. Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401–15. doi:10.1002/sim.5620.
9. FDA Mini-Sentinel Program. Mini-Sentinel project website. http://www.mini-sentinel.org/. Accessed 15 May 2015.
10. Exploring and Understanding Adverse Drug Reactions (EU-ADR) project. EU-ADR project website. http://euadr-project.org/. Accessed 15 May 2015.
11. Toh S, Avorn J, D’Agostino RB, Gurwitz JH, Psaty BM, Rothman KJ, et al. Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf. 2013;22(10):1036–45.
12. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54–60. doi:10.1136/amiajnl-2011-000376.
13. Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36(2):119–34.
14. Coloma P, Avillach P, Salvo F, Schuemie M, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36(1):13–23. doi:10.1007/s40264-012-0002-x.
15. Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(1):33–47.
16. Schneider G, Kachroo S, Jones N, Crean S, Rotella P, Avetisyan R, et al. A systematic review of validated methods for identifying anaphylaxis, including anaphylactic shock and angioneurotic edema, using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(S1):240–7.
17. Lo Re V, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KB, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration’s Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013;22(8):861–72.
18. Noren GN, Hopstadius J, Bate A, Edwards IR. Safety surveillance of longitudinal databases: methodological considerations. Pharmacoepidemiol Drug Saf. 2011;20(7):714–7. doi:10.1002/pds.2151.
19. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512–22.
20. FDA Mini-Sentinel Program. Prospective Routine Observational Monitoring Program Tools (PROMPT) users guide. http://www.mini-sentinel.org/methods/methods_development/details.aspx?ID=1045. Accessed 10 Jan 2014.
21. Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res. 2009;18(1):7–26.
22. Madigan D. Implementing study designs in the OMOP environment. OMOP Symposium Day 1, Workshop 5 Nov. 2013. http://omop.org/sites/default/files/OMOP%20Symposium%20Day%201%20Workshop%205Nov2013%20Madigan%20study%20design.pdf. Accessed 11 May 2015.
23. Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012;23(2):238.
24. Reich CG, Ryan PB, Suchard MA. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S195–204.
25. Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S59–72. doi:10.1007/s40264-013-0099-6.
26. OMOP CDM Specifications version 4.0 and OMOP Standard Vocabulary Specification version 4.4. http://omop.fnih.org. Accessed 30 Oct 2013.
27. Observational Medical Outcomes Partnership. OMOP methods library. http://archive-omop.fnih.org/MethodsLibrary. Accessed 10 Dec 2014.